Industry Groups Praise Intravascular DRG Assignment, Question CMS Methods
This article was originally published in The Gray Sheet
Executive Summary
The Medical Device Manufacturers Association is commending CMS' assignment of intravascular brachytherapy devices to the same diagnosis-related group as coronary stents, but is skeptical of the agency's vague reasoning behind the decision.
You may also be interested in...
"Substantial Improvement" Standard, 50% Cap Remain In Inpatient PPS Rule
Manufacturers will be allowed to appeal to a CMS advisory panel for reconsideration of whether a new technology qualifies as a "substantial improvement" in the diagnosis and treatment of Medicare beneficiaries, according to the agency's inpatient prospective payment system (PPS) final rule.
"Substantial Improvement" Standard, 50% Cap Remain In Inpatient PPS Rule
Manufacturers will be allowed to appeal to a CMS advisory panel for reconsideration of whether a new technology qualifies as a "substantial improvement" in the diagnosis and treatment of Medicare beneficiaries, according to the agency's inpatient prospective payment system (PPS) final rule.
CMS Reviewing ICD Implantation Cost Data, Ensuring DRGs Are Correct
The Centers for Medicare & Medicaid Services (CMS) is evaluating comments on its inpatient prospective payment system (PPS) proposed rule to determine if the actual cost of implanting cardioverter-defibrillators contradicts with the agency's assessment of hospital data on the procedure.